Leo Einck

2.1k total citations
36 papers, 1.6k citations indexed

About

Leo Einck is a scholar working on Molecular Biology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Leo Einck has authored 36 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 20 papers in Infectious Diseases and 14 papers in Epidemiology. Recurrent topics in Leo Einck's work include Tuberculosis Research and Epidemiology (15 papers), Mycobacterium research and diagnosis (12 papers) and Cancer therapeutics and mechanisms (8 papers). Leo Einck is often cited by papers focused on Tuberculosis Research and Epidemiology (15 papers), Mycobacterium research and diagnosis (12 papers) and Cancer therapeutics and mechanisms (8 papers). Leo Einck collaborates with scholars based in United States, Russia and Australia. Leo Einck's co-authors include Carol A. Nacy, Michael Bustin, B. V. Nikonenko, Marina Protopopova, Venkata M. Reddy, Colleen F. Hanrahan, Elena Bogatcheva, Ping Chen, Koen Andries and John H. Klippel and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Journal of Cell Biology.

In The Last Decade

Leo Einck

36 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leo Einck United States 21 847 735 519 273 142 36 1.6k
Gilbert Lanéelle France 25 857 1.0× 766 1.0× 853 1.6× 403 1.5× 133 0.9× 58 1.7k
Anna M. Upton United States 26 1.2k 1.4× 1.2k 1.6× 693 1.3× 335 1.2× 174 1.2× 41 2.0k
James R. Appleman United States 26 1.0k 1.2× 219 0.3× 283 0.5× 203 0.7× 71 0.5× 66 1.7k
Jef Van Gestel Belgium 6 860 1.0× 1.3k 1.7× 850 1.6× 300 1.1× 246 1.7× 8 1.9k
Lluís Ballell Spain 28 1.1k 1.3× 953 1.3× 553 1.1× 701 2.6× 69 0.5× 64 2.1k
Srinivasa P. S. Rao United States 23 1.4k 1.7× 703 1.0× 570 1.1× 378 1.4× 80 0.6× 46 2.4k
Hyungjin Eoh United States 22 1.1k 1.3× 923 1.3× 700 1.3× 73 0.3× 92 0.6× 44 1.9k
Yunyi Wei United States 17 885 1.0× 330 0.4× 438 0.8× 160 0.6× 36 0.3× 31 1.7k
Anthony Vocat Switzerland 14 669 0.8× 697 0.9× 363 0.7× 309 1.1× 71 0.5× 32 1.2k
Joaquim Trias United States 27 1.2k 1.4× 501 0.7× 499 1.0× 249 0.9× 125 0.9× 44 2.4k

Countries citing papers authored by Leo Einck

Since Specialization
Citations

This map shows the geographic impact of Leo Einck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leo Einck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leo Einck more than expected).

Fields of papers citing papers by Leo Einck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leo Einck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leo Einck. The network helps show where Leo Einck may publish in the future.

Co-authorship network of co-authors of Leo Einck

This figure shows the co-authorship network connecting the top 25 collaborators of Leo Einck. A scholar is included among the top collaborators of Leo Einck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leo Einck. Leo Einck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moore, John H., Edward J. van Opstal, Glynis L. Kolling, et al.. (2016). Treatment ofClostridium difficileinfection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model. Journal of Antimicrobial Chemotherapy. 71(5). 1300–1306. 10 indexed citations
2.
Groot, Anne S. De, Leonard Moise, David L. Olive, Leo Einck, & William Martin. (2016). Agility in adversity: Vaccines on Demand. Expert Review of Vaccines. 15(9). 1087–1091. 4 indexed citations
3.
D’Addio, Suzanne M., Venkata M. Reddy, Ying Liu, et al.. (2015). Antitubercular Nanocarrier Combination Therapy: Formulation Strategies and in Vitro Efficacy for Rifampicin and SQ641. Molecular Pharmaceutics. 12(5). 1554–1563. 25 indexed citations
4.
Nikonenko, B. V., Venkata M. Reddy, Elena Bogatcheva, et al.. (2013). Therapeutic Efficacy of SQ641-NE against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 58(1). 587–589. 34 indexed citations
5.
Groot, Anne S. De, Leo Einck, Leonard Moise, et al.. (2013). Making vaccines “on demand”. Human Vaccines & Immunotherapeutics. 9(9). 1877–1884. 15 indexed citations
6.
7.
Reddy, Venkata M., et al.. (2012). SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. Journal of Antimicrobial Chemotherapy. 67(5). 1163–1166. 38 indexed citations
8.
Nikonenko, B. V., Leo Einck, & Carol A. Nacy. (2010). Anti-tuberculosis drug therapy in mice of different inbred strains. Infection Genetics and Evolution. 10(7). 1151–1154. 6 indexed citations
9.
Bogatcheva, Elena, et al.. (2010). Chemical modification of capuramycins to enhance antibacterial activity. Journal of Antimicrobial Chemotherapy. 66(3). 578–587. 34 indexed citations
10.
Bogatcheva, Elena, Manju Yasoda Krishnan, Michael Collins, et al.. (2010). In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria. Journal of Antimicrobial Chemotherapy. 65(12). 2590–2597. 32 indexed citations
11.
Bogatcheva, Elena, Colleen F. Hanrahan, Ping Chen, et al.. (2009). Discovery of dipiperidines as new antitubercular agents. Bioorganic & Medicinal Chemistry Letters. 20(1). 201–205. 30 indexed citations
12.
Nikonenko, B. V., et al.. (2008). Preclinical Study of New TB Drugs and Drug Combinations in Mouse Models. Recent Patents on Anti-Infective Drug Discovery. 3(2). 102–116. 9 indexed citations
13.
Nikonenko, B. V., et al.. (2007). Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs. Antimicrobial Agents and Chemotherapy. 51(4). 1563–1565. 111 indexed citations
14.
Protopopova, Marina, et al.. (2007). In Search of New Cures for Tuberculosis. Medicinal Chemistry. 3(3). 301–316. 43 indexed citations
15.
Reddy, Venkata M., Leo Einck, & Carol A. Nacy. (2007). In Vitro Antimycobacterial Activities of Capuramycin Analogues. Antimicrobial Agents and Chemotherapy. 52(2). 719–721. 57 indexed citations
16.
Green, Shawn J., A H Fortier, J.W. Dijkstra, et al.. (1995). Liposomal Vaccines. Advances in experimental medicine and biology. 383. 83–92. 6 indexed citations
17.
Wang, Yanyan, Robert Dixon, Scott Bowden, et al.. (1993). The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antiviral Research. 21(2). 155–171. 29 indexed citations
18.
Einck, Leo & Michael Bustin. (1983). Inhibition of transcription in somatic cells by microinjection of antibodies to chromosomal proteins.. Proceedings of the National Academy of Sciences. 80(22). 6735–6739. 58 indexed citations
19.
20.
Goguen, Jon D., et al.. (1981). Micrococcal nuclease cleavage of chromatin displays nonrandom properties. Biochemistry. 20(8). 2127–2132. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gilbert Lanéelle Breakdown of academic impact, for papers by Anna M. Upton Breakdown of academic impact, for papers by James R. Appleman Breakdown of academic impact, for papers by Jef Van Gestel Breakdown of academic impact, for papers by Lluís Ballell Breakdown of academic impact, for papers by Srinivasa P. S. Rao Breakdown of academic impact, for papers by Hyungjin Eoh Breakdown of academic impact, for papers by Yunyi Wei Breakdown of academic impact, for papers by Anthony Vocat Breakdown of academic impact, for papers by Joaquim Trias
Rankless by CCL
2026